SNT Stock Overview
Operates as a clinical-stage drug development company that focuses on blood-related cancers in Australia. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Syntara Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.078 |
| 52 Week High | AU$0.084 |
| 52 Week Low | AU$0.014 |
| Beta | 0.56 |
| 1 Month Change | 16.42% |
| 3 Month Change | 81.40% |
| 1 Year Change | 358.82% |
| 3 Year Change | -29.09% |
| 5 Year Change | -46.21% |
| Change since IPO | -82.67% |
Recent News & Updates
Recent updates
Improved Revenues Required Before Syntara Limited (ASX:SNT) Stock's 36% Jump Looks Justified
Jul 05
Syntara Limited (ASX:SNT) Looks Inexpensive After Falling 29% But Perhaps Not Attractive Enough
Apr 29Syntara Limited's (ASX:SNT) Low P/S No Reason For Excitement
Mar 14We're Hopeful That Pharmaxis (ASX:PXS) Will Use Its Cash Wisely
Feb 28Shareholders May Not Be So Generous With Pharmaxis Ltd's (ASX:PXS) CEO Compensation And Here's Why
Oct 27Key Things To Understand About Pharmaxis' (ASX:PXS) CEO Pay Cheque
Mar 01We Think Pharmaxis (ASX:PXS) Can Afford To Drive Business Growth
Jan 04
Shareholder Returns
| SNT | AU Pharmaceuticals | AU Market | |
|---|---|---|---|
| 7D | -2.5% | -1.6% | 0.3% |
| 1Y | 358.8% | -10.3% | 9.1% |
Return vs Industry: SNT exceeded the Australian Pharmaceuticals industry which returned -8.4% over the past year.
Return vs Market: SNT exceeded the Australian Market which returned 9.5% over the past year.
Price Volatility
| SNT volatility | |
|---|---|
| SNT Average Weekly Movement | 16.1% |
| Pharmaceuticals Industry Average Movement | 10.1% |
| Market Average Movement | 8.0% |
| 10% most volatile stocks in AU Market | 16.9% |
| 10% least volatile stocks in AU Market | 3.0% |
Stable Share Price: SNT's share price has been volatile over the past 3 months compared to the Australian market.
Volatility Over Time: SNT's weekly volatility (16%) has been stable over the past year, but is still higher than 75% of Australian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | 21 | Gary Phillips | syntaratx.com.au |
Syntara Limited operates as a clinical-stage drug development company that focuses on blood-related cancers in Australia. The company’s lead product candidate is SNT-5505, which is in Phase 2 trial to treat myelofibrosis, myelodysplastic syndrome, hepatocellular carcinoma, and pancreatic cancer, as well as scar prevention. It also develops SNT-4728 in Phase 2 trial for the treatment of neurodegenerative diseases comprising isolated rapid eye movement sleep behavior disorder (IRBD) and Parkinson’s disease; SNT-5382, which is a selective lysyl oxidase-like 2 inhibitor in Phase 1 trial to treat chronic fibrosis; and SNT-8370 for the treatment of inflammation.
Syntara Limited Fundamentals Summary
| SNT fundamental statistics | |
|---|---|
| Market cap | AU$123.17m |
| Earnings (TTM) | -AU$13.67m |
| Revenue (TTM) | AU$5.76m |
21.4x
P/S Ratio-9.0x
P/E RatioIs SNT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SNT income statement (TTM) | |
|---|---|
| Revenue | AU$5.76m |
| Cost of Revenue | AU$8.30m |
| Gross Profit | -AU$2.53m |
| Other Expenses | AU$11.13m |
| Earnings | -AU$13.67m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.0087 |
| Gross Margin | -43.98% |
| Net Profit Margin | -237.09% |
| Debt/Equity Ratio | 0.2% |
How did SNT perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/10 02:36 |
| End of Day Share Price | 2025/01/10 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2024/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Syntara Limited is covered by 12 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Dennis Hulme | APP Securities Pty Ltd. |
| Anubhav Saxena | Bell Potter |
| Thomas Wakim | Bell Potter |